[go: up one dir, main page]

MX2019011567A - Estatina para la prevención/reducción de daño relacionado con isquemia. - Google Patents

Estatina para la prevención/reducción de daño relacionado con isquemia.

Info

Publication number
MX2019011567A
MX2019011567A MX2019011567A MX2019011567A MX2019011567A MX 2019011567 A MX2019011567 A MX 2019011567A MX 2019011567 A MX2019011567 A MX 2019011567A MX 2019011567 A MX2019011567 A MX 2019011567A MX 2019011567 A MX2019011567 A MX 2019011567A
Authority
MX
Mexico
Prior art keywords
ischemia
prevention
reduction
related damage
statin
Prior art date
Application number
MX2019011567A
Other languages
English (en)
Other versions
MX388159B (es
Inventor
Badimon Maestro Lina
Vilahur Garcia Gemma
Original Assignee
Fundacio Inst De Recerca De L''hospital De La Santa Creu I Sant Pau
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP17164137.6A external-priority patent/EP3381452A1/en
Application filed by Fundacio Inst De Recerca De L''hospital De La Santa Creu I Sant Pau filed Critical Fundacio Inst De Recerca De L''hospital De La Santa Creu I Sant Pau
Publication of MX2019011567A publication Critical patent/MX2019011567A/es
Publication of MX388159B publication Critical patent/MX388159B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción se refiere, en términos generales, a la prevención y/o reducción del daño relacionado con isquemia. De manera más específica, la presente descripción se refiere a compuestos para ser utilizados en la prevención y/o reducción de daño relacionado con isquemia. Los compuestos son estatinas.
MX2019011567A 2017-03-31 2018-03-29 Estatina para la prevención/reducción de daño relacionado con isquemia MX388159B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17164137.6A EP3381452A1 (en) 2017-03-31 2017-03-31 Statin for prevention/reduction of ischemia-related damage
ES201730736 2017-05-26
PCT/EP2018/058158 WO2018178275A1 (en) 2017-03-31 2018-03-29 Statin for prevention/reduction of ischemia-related damage

Publications (2)

Publication Number Publication Date
MX2019011567A true MX2019011567A (es) 2020-01-21
MX388159B MX388159B (es) 2025-03-19

Family

ID=61899251

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019011567A MX388159B (es) 2017-03-31 2018-03-29 Estatina para la prevención/reducción de daño relacionado con isquemia

Country Status (11)

Country Link
US (1) US20200030288A1 (es)
EP (1) EP3600278B1 (es)
CN (1) CN110494134A (es)
BR (1) BR112019020353A2 (es)
CA (1) CA3058250A1 (es)
DK (1) DK3600278T3 (es)
ES (1) ES2877646T3 (es)
MX (1) MX388159B (es)
PL (1) PL3600278T3 (es)
RU (1) RU2768889C2 (es)
WO (1) WO2018178275A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112516126A (zh) * 2020-11-20 2021-03-19 南方医科大学南方医院 普伐他汀的新用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9264598A (en) 1997-08-22 1999-03-16 Gist-Brocades B.V. Statin production by fermentation
PL374126A1 (en) * 2002-05-17 2005-10-03 Esperion Therapeutics, Inc. Methods and copositions for the treatment of ischemic reperfusion
US7166638B2 (en) 2003-05-27 2007-01-23 Nicox S.A. Statin derivatives
CN100502870C (zh) * 2005-07-07 2009-06-24 安徽省现代中药研究中心 含有瑞舒伐他汀或匹伐他汀和b族维生素的药物组合物
AU2007209859A1 (en) * 2006-01-30 2007-08-09 Israel Ben David Bryson Compositions and methods for treating cardiovascular, cerebrovascular and other vascular disease patients
US8183397B2 (en) 2007-04-03 2012-05-22 Lek Pharmaceuticals D.D. Synthesis of statins
EP2271335A1 (en) 2008-04-29 2011-01-12 DSM IP Assets B.V. Improved statin production
CN102171328A (zh) 2008-09-24 2011-08-31 帝斯曼知识产权资产管理有限公司 经改进的斯达汀生产
US10028975B2 (en) * 2010-10-19 2018-07-24 Beth Israel Deaconess Medical Center, Inc. Methods for treating ischemia-reperfusion injury
EP2949324A1 (en) * 2014-05-27 2015-12-02 Consorci Institut Catala de Ciencies Cardiovasculars Prevention and/or treatment of ischemia/reperfusion injury

Also Published As

Publication number Publication date
EP3600278A1 (en) 2020-02-05
EP3600278B1 (en) 2021-01-27
CN110494134A (zh) 2019-11-22
RU2019134491A (ru) 2021-04-30
PL3600278T3 (pl) 2021-08-02
DK3600278T3 (da) 2021-04-26
BR112019020353A2 (pt) 2020-04-28
RU2768889C2 (ru) 2022-03-25
ES2877646T3 (es) 2021-11-17
US20200030288A1 (en) 2020-01-30
MX388159B (es) 2025-03-19
WO2018178275A1 (en) 2018-10-04
RU2019134491A3 (es) 2021-07-16
CA3058250A1 (en) 2018-10-04

Similar Documents

Publication Publication Date Title
CL2020000215A1 (es) Compuestos y composiciones para tratar afecciones asociadas con la actividad nlrp.
CL2017002786A1 (es) Referencia cruzada a solicitudes relacionadas
ECSP18040250A (es) Composiciones y métodos para inhibir la actividad arginasa
CL2018000429A1 (es) Moduladores de la expresión de kras
MX2019007471A (es) Composiciones y métodos para inhibir la actividad de la arginasa.
MX394380B (es) Compuestos dinucleótidos cíclicos para eltratamiento de cáncer
CL2016001082A1 (es) Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa
CL2016001231A1 (es) Compuestos de inhibidor de autotaxina
MX2017002670A (es) Inhibidores de glucosidasa.
CL2016003422A1 (es) Inhibidores de demetilasa-1 específico de lisina
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
CL2015002472A1 (es) Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4.
CL2016002021A1 (es) Ciclopropilaminas como inhibidores lsd1.
EA201691194A1 (ru) Стимуляторы ргц
CL2016003423A1 (es) Inhibidores de demetilasa-1 específico de lisina
MX2015011281A (es) Composiciones de inh-c1 y metodos para la prevencion y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa.
MX2020000386A (es) Inhibidores heterociclicos de la cinasa atr.
DOP2017000111A (es) Inhibidor de cinasa aurora a
CL2017000792A1 (es) Derivados del ácido borónico
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
CL2016002835A1 (es) “compuestos derivados de pladienolida con un resto piridinico; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
CL2015002897A1 (es) Inhibidores de bace1
BR112017000730A2 (pt) derivados de pirrolidinona como inibidores de metap-2
EA201790312A1 (ru) Комбинации лекарственных средств для лечения множественной миеломы
CL2016001349A1 (es) Uso de derivados de bencimidazol-prolina